Table 1.
Baseline demographics and operative findings.
| Number | % | |
|
| ||
| Total | 50 | 100.0 |
| Age at CRS/HIPEC, years | ||
| Median (range) | 50 (14–71) | |
| Gender | ||
| Female | 32 | 64.0 |
| Male | 18 | 36.0 |
| ECOG performance status | ||
| 0 | 41 | 82.0 |
| 1 | 9 | 18.0 |
| Presence of comorbidities | ||
| No | 19 | 38.0 |
| Yes | 31 | 62.0 |
| Primary tumour site | ||
| Colon | 49 | 98.0 |
| Rectum | 1 | 2.0 |
| Histology | ||
| Well differentiated | 6 | 12.0 |
| Moderately differentiated | 27 | 54.0 |
| Poorly differentiated or mucinous | 13 | 26 |
| Signet ring cell | 1 | 2.0 |
| Missing data | 3 | 6.0 |
| Preoperation CEA, μg/L | ||
| Median (range) | 5.1 (0.2–501.0) | |
| Type of CRS procedure | ||
| Subdiaphragmatic stripping | 30 | 60.0 |
| Gastrectomy | 4 | 8.0 |
| Colectomy | 24 | 48.0 |
| Small bowel resection | 21 | 42.0 |
| Splenectomy | 6 | 12.0 |
| THBSO | 15 | 30.0 |
| Cholecystectomy | 8 | 16.0 |
| Bladder resection | 5 | 10.0 |
| Others | 17 | 34.0 |
| Number of CRS procedures performed | ||
| 0 | 1a | 2.0 |
| 1 | 14 | 28.0 |
| 2 | 18 | 36.0 |
| 3 and over | 17 | 34.0 |
| Median (range) | 2 (0–5) | |
| Duration of operation, mins | ||
| Median (range) | 457.5 (120–960) | |
| Completion of Cytoreduction score | ||
| 0 | 49 | 98.0 |
| 1 | 1 | 2.0 |
| ≥2 | 0 | 0 |
| Hospitalization duration, days | ||
| Median (range) | 13.5 (9–43) | |
| Post-CRS/HIPEC adjuvant therapy | ||
| No | 26 | 52.0 |
| Yes | 11 | 22.0 |
| Missing data | 13 | 26.0 |
CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; THBSO, Total Abdominal Hysterectomy Bilateral Salpingo Oophorectomy.
aThe patient had omentectomy.